DRL
Location
Vlaams Brabant
Founded
1980-09-05
Website
Risk Signals
105 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Furniture, Catalog and Mail-Order Houses), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about DRL
Live alerts from global media, monitored by Business Radar
2025-05-12 (businessupturn.com)
Nomura bullish on Dr. Reddy's after strong Q4; raises target price to Rs 1,575 on FY26 growth optimism |
Nomura has upgraded its outlook on Dr. Reddy's Laboratories, reaffirming a 'Buy' rating and raising the target price to ₹1,575, following a stronger-than-expected Q4 performance and optimistic FY26 guidance.DRL reported a net profit of ₹1,587.3 crore
Read more
2024-11-06 (thehansindia.com)
Dr Reddy's clocks 16.51% increase in Q2 revenues
Y-o-y growth primarily driven by global generics revenuesQoQ growth primarily driven by generics revenues in emerging marketsPharma Services and Active Ingredients rose 16.76%Revenues from global generics surged 17.17%
Read more
2024-07-27 (business-standard.com)
Dr Reddy's Laboratories Q1 result: Net profit dips 0.90%, revenue up 13.88%
DRL's growth was primarily driven by the robust performance of the global generics business, particularly in North America and India
Read more
2024-01-29 (moneycontrol.com)
Dr Reddy's Labs Q3 Preview: Revenue, net profit to record tepid growth on lag in domestic sales
Brokerages believe that DRL's commentary on its US base business and margin trend will remain the key monitorable, especially when the contribution from the generic cancer drug Revlimid is expected to gradually taper off through the coming fiscal.
Read more
(thehansindia.com)
DRL Q1 net profit dips slightly
HYDERABAD-BASED global pharma major Dr Reddy's Laboratories Ltd (DRL) has reported a 1.5 per cent decline in its net profit at Rs 571 crore in the quarter (Q1) ended June 30 of this financial year from Rs 579 crore during the same quarter last fiscal.
Read more
(indiatimes.com)
DRL Q1 net up 45% at Rs 663 cr; Israeli is new CEO from Aug 1 - Times of India
India Business News: Hyderabad: Despite price erosion due to increased competition in the US and Europe, and lower sales from PSAI (Pharmaceuticals Services and Active Ing.
Read more